粒细胞集落刺激因子在终末期肝病治疗中的研究进展

摘要/Abstract

摘要： 终末期肝病患者病情重,预后差,治疗棘手。促进肝再生的治疗策略已成为治疗终末期肝病的新思路之一。粒细胞集落刺激因子通过修复紊乱的免疫微环境,刺激骨髓造血干细胞增殖、释放并归巢入肝,促进肝内祖细胞增殖、分化,通过抑制肝细胞凋亡等途径改善终末期肝病患者病情及预后。本文阐述了当前粒细胞集落刺激因子在终末期肝病治疗中的作用机制和研究进展,希望为临床治疗终末期肝病提供有用的参考。

关键词: 粒细胞集落刺激因子, 终末期肝病, 肝再生, 治疗

马元吉, 杜凌遥, 唐红. 粒细胞集落刺激因子在终末期肝病治疗中的研究进展[J]. 肝脏, 2021, 26(11): 1204-1207.

[1] 中华医学会感染病学分会. 终末期肝病合并感染诊治专家共识. 中华肝脏病杂志, 2018,26:568-578.
[2] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019,13:353-390.
[3] Itoh T. Stem/progenitor cells in liver regeneration. Hepatology, 2016,64:663-668.
[4] Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms, and management. Nat Rev Gastroenterol Hepatol, 2016,13:131-149.
[5] Ko S, Russell JO, Molina LM, et al. Liver Progenitors and Adult Cell Plasticity in Hepatic Injury and Repair: Knowns and Unknowns. Annu Rev Pathol, 2020,15:23-50.
[6] Wan Z, You S, Rong Y, et al. CD34+ hematopoietic stem cells mobilization, paralleled with multiple cytokines elevated in patients with HBV-related acute-on-chronic liver failure. Dig Dis Sci, 2013,58:448-457.
[7] Casulleras M, Zhang IW, López-Vicario C, et al. Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells, 2020,9:2632.
[8] Wu W, Sun S, Wang Y, et al. Circulating Neutrophil Dysfunction in HBV-Related Acute-on-Chronic Liver Failure. Front Immunol, 2021,12:620365.
[9] Di Campli C, Zocco MA, Saulnier N, et al. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis, 2007,39:1071-1076.
[10] Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology, 2012,142:505-512.e1.
[11] Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol, 2013,19:1104-1110.
[12] 许祥, 刘晓燕, 陈婧, 等. 粒细胞集落刺激因子治疗乙型肝炎相关慢加急性肝衰竭随机对照临床研究. 传染病信息, 2016,29:279-283.
[13] Spahr L, Lambert JF, Rubbia-Brandt L, et al. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology, 2008,48:221-229.
[14] Prajapati R, Arora A, Sharma P, et al. Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial. Eur J Gastroenterol Hepatol, 2017,29:448-455.
[15] Singh V, Keisham A, Bhalla A, et al. Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis. Clin Gastroenterol Hepatol, 2018,16:1650-1656.e2.
[16] Shasthry SM, Sharma MK, Shasthry V, et al. Efficacy of Granulocyte Colony-stimulating Factor in the Management of Steroid-Nonresponsive Severe Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial. Hepatology, 2019,70:802-811.
[17] Kedarisetty CK, Anand L, Bhardwaj A, et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology, 2015,148:1362-1370.e7.
[18] Fiuza C, Salcedo M, Clemente G, et al. Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol, 2002,9:433-439.
[19] Rolando N, Clapperton M, Wade J, et al. Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure. Eur J Gastroenterol Hepatol, 2000,12:1135-1140.
[20] Alvarenga DM, Mattos MS, Lopes ME, et al. Paradoxical Role of Matrix Metalloproteinases in Liver Injury and Regeneration after Sterile Acute Hepatic Failure. Cells, 2018,7:247.
[21] Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol, 2014,109:1417-1423.
[22] Anand L, Bihari C, Kedarisetty CK, et al. Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis. Liver Int, 2019,39:115-126.
[23] Piscaglia AC, Arena V, Passalacqua S, et al. A case of granulocyte-colony stimulating factor/plasmapheresis-induced activation of granulocyte-colony stimulating factor-positive hepatic progenitors in acute-on-chronic liver failure. Hepatology, 2015,62:649-652.
[24] 康文, 刘正稳, 韩群英, 等. 粒细胞集落刺激因子对大鼠急性肝衰竭肝细胞凋亡的影响. 中华医学杂志, 2008:980-984.
[25] Chen H, Tang S, Liao J, et al. Therapeutic effect of human umbilical cord blood mesenchymal stem cells combined with G-CSF on rats with acute liver failure. Biochem Biophys Res Commun, 2019,517:670-676.
[26] 周培, 于淙, 渠淑云. 集落刺激因子治疗终末期酒精性肝病的临床对照研究. 肝脏, 2020,25:521-524.
[27] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 中华肝脏病杂志, 2019:18-26.
[28] Saha BK, Mahtab MA, Akbar S, et al. Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage. Hepatol Int, 2017,11:540-546.
[29] Philips CA, Augustine P, Rajesh S, et al. Granulocyte?Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit. J Clin Exp Hepatol, 2020,10:124-134.
[30] De A, Kumari S, Singh A, et al. Multiple Cycles of Granulocyte Colony-Stimulating Factor Increase Survival Times of Patients with Decompensated Cirrhosis in a Randomized Trial. Clin Gastroenterol Hepatol, 2021,19:375-383.e5.
[31] Verma N, Kaur A, Sharma R, et al. Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial. Hepatology, 2018,68:1559-1573.
[32] Newsome PN, Fox R, King AL, et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol, 2018,3:25-36.
[33] Becker P, Schwebig A, Brauninger S, et al. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance. Transfusion, 2016,56:3055-3064.

粒细胞集落刺激因子在终末期肝病治疗中的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肖倩倩, 王梦雨, 范建高. 非酒精性脂肪性肝病综合诊疗模式[J]. 肝脏, 2021, 26(9): 951-952.
[2]	孟方园, 孙悦, 苑广菲, 高沿航. 噬菌体在酒精性肝病治疗中的应用进展[J]. 肝脏, 2021, 26(9): 956-957.
[3]	许梓萌, 李德瑶, 席婧媛, 鲁凤民. 从HBV X蛋白的生物学功能看靶向HBx临床治愈慢性乙型肝炎的可能性[J]. 肝脏, 2021, 26(8): 832-834.
[4]	张思越, 甘建和. 慢加急性肝衰竭防治的研究进展[J]. 肝脏, 2021, 26(8): 928-931.
[5]	刘玉, 邹颖, 张正国, 郭红英, 梅雪, 王介非, 钱志平. 糖皮质激素成功救治急性肝衰竭1例[J]. 肝脏, 2021, 26(8): 945-946.
[6]	殷霖霖, 赵思, 张秀华, 季国忠. 混合型肝细胞-胆管癌的诊疗进展[J]. 肝脏, 2021, 26(7): 720-723.
[7]	黄晓铨, 吴玲, 姜思雨, 李锋, 陈世耀. 丙型肝炎持续病毒应答与肝硬化食管胃静脉曲张患者内镜治疗后再出血的相关性[J]. 肝脏, 2021, 26(6): 597-601.
[8]	段兴刚, 刘立, 刘良婷, 王应甜, 范群雄. 慢性乙型肝炎患者停药导致肝衰竭发生的特征及影响预后的相关因素分析[J]. 肝脏, 2021, 26(6): 617-620.
[9]	梁书菀. 肝癌合并门静脉癌栓微创治疗的进展分析[J]. 肝脏, 2021, 26(6): 703-705.
[10]	吉晓妹, 邵春燕, 吉浩明, 顾春燕. 人血白蛋白序贯治疗对原发性肝癌合并肝硬化患者射频消融术后肝功能和预后的影响[J]. 肝脏, 2021, 26(5): 534-537.
[11]	董晓锋, 杨英豪, 张燕, 王建斌, 朱晓红, 刘妲妲, 梁栋. 原发性肝癌治疗现状及MDT治疗模式的探讨[J]. 肝脏, 2021, 26(3): 262-265.
[12]	史冬梅, 刘芸野, 王伟静, 项晓刚. 成人慢性活动性EB病毒感染的临床特点及预后分析[J]. 肝脏, 2021, 26(2): 182-186.
[13]	高得勇, 娄小丽, 马爽, 张昆仑, 刘亮明, 刘鸿翔. 乙型肝炎肝硬化抗病毒治疗前后抗原特异性CD8⁺T细胞功能分析[J]. 肝脏, 2021, 26(11): 1250-1252.
[14]	陈镜宇, 范建高. 代谢相关脂肪性肝病的危害和饮食治疗对策[J]. 肝脏, 2021, 26(11): 1287-1289.
[15]	中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J]. 肝脏, 2021, 26(10): 1057-1068.